Final analysis of a phase II study of nivolumab in combination with ipilimumab for unresectable chemotherapy‐naive advanced melanoma

Nivolumab plus ipilimumab combination is currently one of the preferred regimens for advanced melanoma in recently updated clinical practice guidelines. However, the evidence on the efficacy of the combination for acral or mucosal subtypes remains less robust. This is the final analysis of a multice...

Descripción completa

Detalles Bibliográficos
Autores principales: Namikawa, Kenjiro, Kiyohara, Yoshio, Takenouchi, Tatsuya, Uhara, Hisashi, Uchi, Hiroshi, Yoshikawa, Shusuke, Takatsuka, Sumiko, Koga, Hiroshi, Wada, Naoko, Minami, Hironobu, Hatsumichi, Masahiro, Namba, Yoshinobu, Yamazaki, Naoya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7693067/
https://www.ncbi.nlm.nih.gov/pubmed/32812243
http://dx.doi.org/10.1111/1346-8138.15514

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7693067/
https://www.ncbi.nlm.nih.gov/pubmed/32812243
http://dx.doi.org/10.1111/1346-8138.15514

Ejemplares similares